CAR-T
-
A compact glossary
Terms are explained here; proprietary or validated scoring instruments are not reproduced.
-
The questions readers actually ask
Direct answers without turning uncertainty into either hype or pessimism.
-
A better consultation: questions and a referral worksheet
Original educational tools by Olga Goodman, MD. Not validated scores.
-
Access, cost and the burden around treatment
The economic question is larger than the price of a cellular product.
-
Clinical trials: finding the right question and checking access
A registry record is a starting point, not a promise that a study is currently enrolling.
-
CAR-NK, CAAR-T and direct antifibrotic targeting
Three adjacent directions that expand the possibilities—and answer different biological questions.
-
What comes next: donor cells, RNA and in vivo engineering
Different innovations solve different problems—and introduce different uncertainties.
-
CAR-T, B-cell antibodies, AHSCT and bispecifics
The relevant question is which strategy offers the best patient-centered result—not which sounds most advanced.
-
How to read remission, response and “drug-free” claims
A common language prevents both exaggerated optimism and unjustified dismissal.
-
Durability, relapse and the meaning of B-cell return
The strongest promise of CAR-T requires the longest and most careful observation.